Literature DB >> 26970477

Microsurgical Management of Craniopharyngiomas via a Unilateral Subfrontal Approach: A Retrospective Study of 177 Continuous Cases.

Can Du1, Cheng-Yuan Feng2, Xian-Rui Yuan3, Qing Liu2, Ze-Feng Peng2, Xing-Jun Jiang2, Xue-Jun Li2, Ge-Lei Xiao1, Yi-Feng Li1, Tao Xiong1.   

Abstract

OBJECTIVE: To evaluate the outcomes of 177 cases of craniopharyngioma (CP) treated via a unilateral subfrontal approach.
METHODS: A total of 177 continuous microscopic surgeries were performed by the senior author (Y.X.). The tumors were divided into 6 groups using the diaphragm sellae and the third ventricle floor as the anatomic references. The preoperative, postoperative, and long-term follow-up data were analyzed to evaluate the extent of tumor resection, recurrence, and functional status.
RESULTS: The subfrontal-basal approach was used in 169 (91.4%) cases. Total resection was achieved in 167 (94.4%) cases. A total of 158 patients were followed from 6 to 130 months. There were 3 perioperative and 23 delayed deaths. Twenty-two patients had tumor recurrence (12.7%). The progression-free survival was 80% at 5 years and 72% at 10 years. The overall survival was 84.0% at 2.5 years and 83.2% at 10 years. There was a significant increase of pituitary dysfunction after total resection. Neurologic function was stable in most patients. Rate of hypothalamic dysfunction and mortality were higher in patients with intraventricular CPs. Of the surviving patients, 91.8% were living independently with acceptable morbidities at the end of the study.
CONCLUSIONS: Most CPs extend along the intrasellar-suprasellar-third ventricle axis. A subfrontal-basal approach is a simple, safe, and effective approach to resecting CPs extending along the vertical axis. A translamina terminalis approach is an ideal corridor to resect intraventricular CP. The benefit of radical resection remains controversial, especially for CPs involving the infundibulotuberal region.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Craniopharyngioma; Gross total resection; Lamina terminalis; Microsurgery; Quality of life; Retrochiasmatic; Subfrontal approach; Third ventricle

Mesh:

Year:  2016        PMID: 26970477     DOI: 10.1016/j.wneu.2016.03.002

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

Review 1.  Excess mortality after craniopharyngioma treatment: are we making progress?

Authors:  Nidan Qiao
Journal:  Endocrine       Date:  2018-12-19       Impact factor: 3.633

Review 2.  Strictly third ventricle craniopharyngiomas: pathological verification, anatomo-clinical characterization and surgical results from a comprehensive overview of 245 cases.

Authors:  Ruth Prieto; Laura Barrios; José M Pascual
Journal:  Neurosurg Rev       Date:  2021-08-27       Impact factor: 3.042

3.  Comparative analysis on microsurgical removal of craniopharyngioma via lateral supraorbital approach and standard pterional approach.

Authors:  Chongshun Zhao; Zhouqing Chen; Na Xu; Tao Xue; Xin Wu; Wanchun You; Yun Zhu; Zhong Wang
Journal:  Chin Neurosurg J       Date:  2018-08-01

4.  Trans-eyebrow supraorbital keyhole approach in suprasellar and third ventricular craniopharyngioma surgery: the experience of 27 cases and a literature review.

Authors:  Meiqin Cai; Zhuopeng Ye; Cong Ling; Baoyu Zhang; Bo Hou
Journal:  J Neurooncol       Date:  2018-11-03       Impact factor: 4.130

5.  Relationship between postoperative hypothalamic injury and water and sodium disturbance in patients with craniopharyngioma: A retrospective study of 178 cases.

Authors:  Can Du; Yueshuang Leng; Quanwei Zhou; Ju-Xiong Xiao; Xian-Rui Yuan; Jian Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-02       Impact factor: 6.055

6.  Microsurgical treatment of craniopharyngioma: Experiences on 183 consecutive patients.

Authors:  Shi-Yu Feng; Yan-Yang Zhang; Xin-Guang Yu; Xiao-Lei Chen; Tao Zhou; Bo Bu; Jin-Li Jiang
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.